CLINICAL ROLE -
March 25th 2025
Pharmacists can promote prevention through the implementation of antimicrobial stewardship initiatives and advocate for fecal microbiota transplant.
March 21st 2025
The new indication for guselkumab in Crohn disease builds off a previous approval in ulcerative colitis, providing patients a treatment option for the major forms of inflammatory bowel disease.
March 19th 2025
The combination was approved for treatment of patients with gastroesophageal junction (GEJ) adenocarcinoma.
March 7th 2025
The treatment is currently undergoing evaluation in an investigational preclinical program and is projected to be in human trials in 2026.
March 5th 2025
The designation was granted after positive results from the phase 1 STOMP-I clinical trial (NCT01915927).
Self-Care for Cold and Cough
Recommendations regarding OTC products for treatment of chronic dry cough, cold prevention, general symptom relief, and nasal congestion.
Read More
A Therapeutic Option for the Management of Gastroesophageal Reflux Disease
Some patients with gastroesophageal reflux disease also experience erosive esophagitis from acid-related mucosal injury, which will require careful treatment.